SCHEMBL20073167

SCHEMBL20073167

COc1ccc(CN(c2ccncn2)S(=O)(=O)c2ccc(N)cc2F)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
TP53 P04637 1/20 0.37
GAA P10253 2/20 0.34
RAPGEF3 O95398 1/20 0.34
GFER P55789 2/20 0.34
MAPK1 P28482 1/20 0.34
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DHFR P00374 1/20 0.33
CYP19A1 P11511 1/20 0.33
RORC P51449 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15465002 0.91 POLB (0.39) POLBTP53GAAMAPK1LMNA
SCHEMBL30201222 0.91 POLB (0.39) POLBTP53GAAMAPK1LMNA
SCHEMBL20095706 0.90 POLB (0.39) POLBTP53GAAGFERMAPK1
SCHEMBL29481979 0.90 POLB (0.41) POLBTP53GAAMAPK1LMNA
SCHEMBL14934588 0.90 POLB (0.41) POLBTP53GAAMAPK1LMNA
SCHEMBL29481973 0.89 POLB (0.40) POLBMAPK1LMNACYP19A1MEN1
SCHEMBL20095675 0.88 POLB (0.37) POLBTP53GAALMNAL3MBTL1
SCHEMBL21312177 0.88 POLB (0.39) POLBTP53GAAMAPK1LMNA
SCHEMBL20095731 0.88 POLB (0.37) POLBTP53GAAMAPK1LMNA
SCHEMBL15464546 0.87 HDAC8 (0.39) POLBTP53GAAGFERLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200115354-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2020-04-16 US disclosed
US-10457654-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2019-10-29 US disclosed
WO-2018072602-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-04-26 WO disclosed
US-20180105504-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115354-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF NPY5R, REN, F12 POLB 4679/4885TP53 1989/4885GAA 2055/4885
US-10457654-B2 Therapeutic compounds and methods of use thereof NPY5R, REN, F12 POLB 4679/4885TP53 1989/4885GAA 2055/4885
US-20180105504-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF NPY5R, REN, F12 POLB 4677/4885TP53 2072/4885GAA 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.